Fertigel

⚕ For Healthcare Professionals Schedule H · Rx Only Information for prescribing andrologists, sexologists & endocrinologists

Fertigel — 1% Transdermal Testosterone Gel for Low Testosterone (India)

℞ Schedule H Prescription Drug Rx Only · Topical

FertiGel 1%

For precise, physiologic testosterone replacement therapy

Testosterone 50 mg / 5 g · Transdermal Gel · 1% w/w
Common Clinical Indications
  • Hypogonadism due to pituitary or testicular disorders
  • Androgen deficiency symptoms (fatigue, ↓ libido, ED)
  • Late-onset hypogonadism / andropause
  • Delayed puberty
  • Post-orchiectomy testosterone deficiency
  • Supportive therapy in infertility / metabolic conditions related to low T
Recommended Dosage One 5 g sachet (50 mg) once daily Apply to clean, dry skin of shoulders / upper arms / abdomen — adjust per serum testosterone & clinical response
10 × 5 gSachets per pack
50 mgTestosterone / sachet
10 mg/g1% w/w concentration
▶ Watch Application Video 📱 Talk to a Doctor on WhatsApp For Clinics — Order Direct
Manufactured by: Fertillmed Pharmaceuticals Pvt. Ltd. · Tamil Nadu, India · Marketed under Fertillmed Andrology
Clinical context

Symptoms of testosterone deficiency

Hypogonadism affects three domains. Recognising the cluster of physical, sexual and psychological symptoms is the first step toward treatment.

Physical

  • ↓ Muscle mass
  • ↑ Body fat
  • ↓ Bone density
  • ↓ Strength & endurance

Sexual

  • ↓ Libido
  • Erectile dysfunction
  • Infertility
  • Reduced morning erections

Psychological

  • Fatigue
  • Low mood / depression
  • Poor concentration
  • Reduced motivation
Efficacy data · Indicative

Effect of FertiGel 1% on sexual function over 12 weeks

Indicative trajectory of IIEF (International Index of Erectile Function) scores during consistent daily transdermal application. Individual response varies — serum testosterone monitoring is recommended.

Effect of FertiGel 1% on Sexual Function (IIEF Score) 1012141618202224262830 1217212528 024812 Weeks of TreatmentIIEF Score
+133%Score gain (12 wk)
Wk 2First measurable rise
Wk 12Plateau toward normal
1×/dayConsistent application
Reading the chart. Baseline IIEF score of 12 (severe ED range) progressively rises through weeks 2 (17), 4 (21), 8 (25) and 12 (28) — bringing patients within the no-to-mild ED band. The trajectory illustrates a steady rise in sexual performance and satisfaction as testosterone levels normalise with consistent transdermal application. Educational illustration; not from a single FertiGel-specific clinical trial.
Detailed indications

Six clinical scenarios where FertiGel 1% is indicated

1

Primary & Secondary Hypogonadism

Pituitary or testicular disorders confirmed by serum testosterone & LH/FSH workup.

2

Androgen Deficiency Symptoms

Fatigue, reduced libido, erectile dysfunction with confirmed low serum total testosterone.

3

Late-Onset Hypogonadism / Andropause

Age-related testosterone decline with classical symptom cluster in older adult males.

4

Delayed Puberty

As part of clinically supervised pubertal induction protocols when indicated.

5

Post-Orchiectomy

Testosterone deficiency following surgical removal of one or both testes.

6

Supportive in Infertility / Metabolic

Adjunctive therapy in specific male infertility protocols and metabolic conditions linked to hypogonadism.

Patient counselling · Application support

Video-guided application for compliance

Each pack includes a step-by-step illustrated leaflet plus a QR code linking to the official application video — designed to support correct technique and patient adherence.

What the video covers

Site selection, dose measurement, application technique, drying time, hand-washing, and post-application precautions to avoid secondary transfer.

▶ Watch on YouTube
1
Clean & Dry

Skin of shoulders, upper arms or abdomen. Free of oils, lotions or residue.

2
Apply 1 Sachet

One 5 g sachet (50 mg testosterone) once daily — same time each day.

3
Allow to Dry

5–10 minutes drying time before dressing. Wash hands with soap & water.

4
Avoid Transfer

No skin-to-skin contact at site for 2+ hours. Cover area with clothing.

For prescribers · For clinics

Speak to our medical team

FertiGel™ 1% is supplied directly to andrologist, sexologist and endocrinologist clinics across India and Nepal — with patient counselling collateral, dispensing terms and prescribing-information packs. Contact our medical reps via WhatsApp.

Talk to Medical Team For Clinics — Order Direct
Prescriber FAQ

Frequently asked questions

What is FertiGel™ 1%?
FertiGel™ 1% is a topical transdermal testosterone gel containing 50 mg testosterone per 5 g sachet (10 mg testosterone per gram of gel). It is a Schedule H prescription drug indicated for testosterone replacement therapy (TRT) in adult males with confirmed hypogonadism.
Who is FertiGel™ 1% indicated for?
FertiGel™ 1% is indicated for adult males with primary or secondary hypogonadism (pituitary/testicular), late-onset hypogonadism (andropause), androgen deficiency symptoms (fatigue, reduced libido, erectile dysfunction), delayed puberty, post-orchiectomy testosterone deficiency, and as supportive therapy in specific infertility and metabolic conditions related to low testosterone.
How is FertiGel™ 1% applied?
Apply once daily to clean, dry, intact skin of the shoulders, upper arms or abdomen, as directed by the prescribing physician. Allow the gel to dry for 5–10 minutes before dressing. Wash hands thoroughly with soap and water after application. Avoid skin-to-skin contact with women and children at the application site for at least 2 hours after application.
What is the recommended dosage?
Recommended starting dose: one 5 g sachet (50 mg testosterone) applied once daily, as prescribed by your physician. Dose may be adjusted based on serum testosterone levels and clinical response. Always follow the prescribing clinician's instructions.
What is the expected efficacy timeline?
Clinical research with similar 1% testosterone gel formulations shows progressive improvement in IIEF (International Index of Erectile Function) scores over 12 weeks of consistent daily application. Indicative trajectory: baseline ~12 → week 2 ~17 → week 4 ~21 → week 8 ~25 → week 12 ~28. Individual response varies; serum testosterone monitoring is recommended.
Is it Schedule H?
Yes. FertiGel™ 1% is a Schedule H prescription drug in India. It can only be sold by retail pharmacies on the prescription of a Registered Medical Practitioner. Self-medication is not permitted.
What are the contraindications?
FertiGel™ 1% is contraindicated in: men with known or suspected carcinoma of the breast or prostate, severe cardiac disease, severe hepatic or renal disease, hypersensitivity to testosterone or any excipient, women (especially during pregnancy and lactation), and children. Always consult the full prescribing information.
What patient counselling support is available?
Each pack includes a step-by-step application leaflet, plus a QR code linking to the official application video on YouTube. The video walks the patient through site selection, application technique, and post-application precautions. View at https://youtu.be/AduH818V5FM?si=h-GSD8Vw0j_nMkUe.
How can clinics order FertiGel™ 1%?
Sexologist, andrologist and endocrinologist clinics across India and Nepal can order FertiGel™ 1% directly from Fertillmed via our medical representatives. Contact +91 93635 35303 on WhatsApp for clinic pricing, dispensing terms and patient counselling collateral.
Where is FertiGel™ 1% manufactured?
FertiGel™ 1% is manufactured in India by Fertillmed Pharmaceuticals Private Limited, Mulangudi Post, Kodavasal Taluk, Tamil Nadu — a DPIIT-recognised, FSSAI-licensed pharmaceutical company. Marketed under the Andrology range.
Important Schedule H Rx information. FertiGel™ 1% (Testosterone USP 10 mg per gram, transdermal gel, 1% w/w) is a Schedule H prescription drug under the Drugs and Cosmetics Rules, 1945 (India). It cannot be sold by retail without the prescription of a Registered Medical Practitioner. For topical use only — not for oral or injectable use. Indicated for adult males with confirmed hypogonadism. Contraindicated in: known/suspected carcinoma of breast or prostate, severe cardiac/hepatic/renal disease, hypersensitivity to testosterone or any excipient, women (especially pregnancy / lactation), and children. Avoid skin contact transfer to women and children for at least 2 hours after application — wash hands thoroughly post-application and cover the application site. Periodic monitoring of serum testosterone, hematocrit, lipid profile, prostate-specific antigen (PSA) and digital rectal examination is recommended in line with prevailing prescribing guidelines. Discontinue and consult prescriber if any adverse reaction occurs. Keep out of reach of children. The IIEF score trajectory shown above is indicative and educational; individual patient response varies. Manufactured by Fertillmed Pharmaceuticals Pvt. Ltd., Mulangudi Post, Kodavasal Taluk, Tamil Nadu, India. DPIIT-recognised · FSSAI-licensed.

▶ Video WhatsApp